Center for Advanced Retinal and Ocular Therapeutics, F. M. Kirby Center for Molecular Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States.
Invest Ophthalmol Vis Sci. 2018 Mar 1;59(3):1212-1220. doi: 10.1167/iovs.17-22972.
Optic neuritis is a condition defined by autoimmune-mediated demyelination of the optic nerve and death of retinal ganglion cells. SIRT1 and NRF2 stimulate anti-inflammatory mechanisms and have previously demonstrated therapeutic value in preclinical models of neurodegenerative disease. Here we investigated the neuroprotective potential of SIRT1 or NRF2 gene transfer using adeno-associated virus (AAV) vectors in the experimental autoimmune encephalomyelitis (EAE) model of multiple sclerosis.
C57Bl/6J mice were administered intravitreal doses of AAV2 vectors and immunized to induce EAE symptoms. Visual function was examined by recording the optokinetic response (OKR) just prior to EAE induction and once every 7 days postinduction for 7 weeks. Retina and optic nerves were harvested to investigate retinal ganglion cell survival (immunolabeling with Brn3a antibodies); inflammation (hematoxylin and eosin staining); and demyelination (luxol fast blue staining).
Animals modeling EAE demonstrate reduced visual acuity compared to sham-induced controls. Intravitreal delivery of AAV2-NRF2 did not preserve visual function. However, AAV2-SIRT1 mediated significant preservation of the OKR compared to AAV2-eGFP controls. Treatment with AAV2-NRF2 promoted RGC survival while AAV2-SIRT1 mediated an upward trend in protection compared to vehicle and AAV2-eGFP controls. Neither NRF2 nor SIRT1 gene augmentation was able to suppress optic nerve inflammation or demyelination.
AAV-mediated overexpression of NRF2 or SIRT1 within RGCs mediates distinct neuroprotective effects upon visual function and RGC survival. This study expands our understanding of SIRT1 and NRF2-mediated neuroprotection in the context of MS pathogenesis and optic neuropathies.
视神经炎是一种由自身免疫介导的视神经脱髓鞘和视网膜神经节细胞死亡引起的疾病。SIRT1 和 NRF2 可刺激抗炎机制,并且在神经退行性疾病的临床前模型中已显示出治疗价值。在此,我们使用腺相关病毒(AAV)载体研究了 SIRT1 或 NRF2 基因转移在多发性硬化症的实验性自身免疫性脑脊髓炎(EAE)模型中的神经保护潜力。
C57Bl/6J 小鼠接受 AAV2 载体的玻璃体内剂量给药,并进行免疫接种以诱导 EAE 症状。在 EAE 诱导之前和诱导后每周一次通过记录光运动反应(OKR)来检查视觉功能,持续 7 周。收获视网膜和视神经以研究视网膜神经节细胞的存活(用 Brn3a 抗体进行免疫标记);炎症(苏木精和伊红染色);和脱髓鞘(卢索快速蓝染色)。
EAE 模型动物的视力与假手术诱导的对照相比降低。AAV2-NRF2 的玻璃体内给药不能维持视觉功能。然而,与 AAV2-eGFP 对照相比,AAV2-SIRT1 介导了 OKR 的显著保留。AAV2-NRF2 的治疗促进了 RGC 的存活,而与载体和 AAV2-eGFP 对照相比,AAV2-SIRT1 介导了保护作用的上升趋势。NRF2 或 SIRT1 基因扩增均不能抑制视神经炎症或脱髓鞘。
在 RGC 中,AAV 介导的 NRF2 或 SIRT1 的过表达在视觉功能和 RGC 存活方面介导了不同的神经保护作用。这项研究扩展了我们对 SIRT1 和 NRF2 介导的多发性硬化症发病机制和视神经病变中的神经保护作用的理解。